The National University Hospital (NUH) and Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (RJH) have inaugurated the Singapore-Shanghai Medical Innovation Centre (SSMIC) to spearhead advancements in healthcare. Launched on 15 October during the 6th Singapore-Shanghai Comprehensive Cooperation Council meeting in Shanghai, the centre aims to foster collaboration in cell and gene therapy and orthopaedics.
The SSMIC is the first initiative stemming from a Memorandum of Understanding signed in 2024, aimed at establishing a framework for clinical cooperation. Co-chaired by Aymeric Lim, CEO of NUH, and Ning Guang, President of RJH, the centre will focus on developing proof-of-concept methodologies and conducting translational research.
Initial projects will include clinical trials for a novel Chimeric Antigen Receptor (CAR) T-cell therapy, which uses a patient’s immune system to target cancer cells. This personalised treatment aims to provide effective solutions for patients unresponsive to first-line treatments. In orthopaedics, the centre will explore 3D printing for musculoskeletal tumour resection and reconstruction, enhancing surgical outcomes and recovery.
The centre is designed to be a dynamic platform for ongoing collaboration. “In the face of ever-evolving health challenges, it is paramount that we continuously innovate,” said Aymeric Lim. Ning Guang added, “With support from Shanghai and Singapore, I have faith we will succeed.”
The SSMIC represents a significant step in advancing patient care, with plans to expand its scope and ensure a continuous pipeline of clinical breakthroughs.
